CompletedPhase 2NCT01209325
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Studying Malignant tumor of penis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AIDS Malignancy Consortium
- Principal Investigator
- Joel Palefsky, MDUniversity of California, San Francisco
- Intervention
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(biological)
- Enrollment
- 149 enrolled
- Eligibility
- 13-26 years · MALE
- Timeline
- 2011 – 2017
Study locations (18)
- Moores UCSD Cancer Center, La Jolla, California, United States
- UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States
- John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
- Ruth M. Rothstein Core Center at Cook County Hospital, Chicago, Illinois, United States
- Fenway Community Health, Boston, Massachusetts, United States
- Boston University Cancer Research Center, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Laser Surgery Care, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
- St. Jude's Children's Research Hospital, Memphis, Tennessee, United States
- Thomas Street Health Center, Houston, Texas, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · The Emmes Company, LLC · University of Arkansas · Merck Sharp & Dohme LLC · AIDS and Cancer Specimen Resource
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01209325 on ClinicalTrials.govOther trials for Malignant tumor of penis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07110038DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGPHASE2NCT06353906Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile CancerThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT06465914A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese MalesShanghai Bovax Biotechnology Co., Ltd.
- ENROLLING BY INVITATIONNCT06565585Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell CarcinomaUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06415318TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile CancerSun Yat-sen University
- RECRUITINGPHASE1NCT05999396FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal CancerGerman Cancer Research Center
- RECRUITINGPHASE2NCT06104618Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the PenisMayo Clinic
- RECRUITINGNANCT05899361A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of InterestDana-Farber Cancer Institute